Dr. Martin E Gutierrez
Claim this profileJohn Theurer Cancer Center at Hackensack University Medical Center
Expert in Solid Tumors
Expert in Tumors
40 reported clinical trials
77 drugs studied
About Martin E Gutierrez
Education:
- Obtained MD from the University of Texas Southwestern Medical School, Dallas, TX.
Experience:
- Completed Residency in Internal Medicine at the University of Texas Southwestern Medical Center, Dallas, TX.
- Undertook Fellowship in Hematology and Oncology at the same institution.
- Serving as an attending physician at the John Theurer Cancer Center at Hackensack University Medical Center, with a specialization in hematology and oncology.
Area of expertise
1Solid Tumors
Global LeaderStage IV
Stage III
KRAS positive
2Tumors
Global LeaderStage IV
Stage III
KRAS positive
Affiliated Hospitals
Clinical Trials Martin E Gutierrez is currently running
CLN-619 + Pembrolizumab
for Cancer
This study is evaluating whether a drug called CLN-619 can be used to treat cancer.
Recruiting1 award Phase 110 criteria
SAR445877
for Advanced Cancer
This is a Phase 1/2, open label, multiple cohort study to assess the safety and preliminary efficacy of SAR445877 as a monotherapy or in combination with other anticancer therapies for participants aged at least 18 years with advanced unresectable or metastatic solid tumors. The study will include 2 parts: A dose escalation Part 1: for finding the therapeutic dose(s) of SAR445877 in a monotherapy given every 2 weeks (Q2W) or weekly (QW) and in combination with other anticancer therapies when applicable. A multicohort dose expansion/dose optimization Part 2: for the assessment of safety and preliminary efficacy of SAR445877 in monotherapy and in combination with cetuximab: 2 recommended doses for expansion/optimization of SAR445877 identified from dose escalation part 1 will be tested in different indications in monotherapy and in combination with other anticancer therapies as applicable. Approximately 285 participants will be enrolled to the study intervention: approximately 75 participants in part 1 and up to 210 participants in expansion/dose optimization part (part 2).
Recruiting1 award Phase 1 & 2
More about Martin E Gutierrez
Clinical Trial Related2 years of experience running clinical trials · Led 40 trials as a Principal Investigator · 20 Active Clinical TrialsTreatments Martin E Gutierrez has experience with
- Nivolumab
- Pembrolizumab
- Ipilimumab
- Docetaxel
- Carboplatin
- Capecitabine
Breakdown of trials Martin E Gutierrez has run
Solid Tumors
Tumors
Cancer
Lung Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Martin E Gutierrez specialize in?
Martin E Gutierrez focuses on Solid Tumors and Tumors. In particular, much of their work with Solid Tumors has involved Stage IV patients, or patients who are Stage III.
Is Martin E Gutierrez currently recruiting for clinical trials?
Yes, Martin E Gutierrez is currently recruiting for 20 clinical trials in Hackensack New Jersey. If you're interested in participating, you should apply.
Are there any treatments that Martin E Gutierrez has studied deeply?
Yes, Martin E Gutierrez has studied treatments such as Nivolumab, Pembrolizumab, Ipilimumab.
What is the best way to schedule an appointment with Martin E Gutierrez?
Apply for one of the trials that Martin E Gutierrez is conducting.
What is the office address of Martin E Gutierrez?
The office of Martin E Gutierrez is located at: John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey 07601 United States. This is the address for their practice at the John Theurer Cancer Center at Hackensack University Medical Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.